Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 7/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.48 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.46 |
| ▸ | HPGDS | O60760 | 3/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | RET | P07949 | 1/20 | 0.43 |
| ▸ | WNT1 | P04628 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15431347 | 0.95 | IRAK1 (0.56) | IRAK1GPR119USP30IRAK4HPGDS | |
| SCHEMBL15416264 | 0.93 | IRAK1 (0.58) | IRAK1GPR119USP30IRAK4RET | |
| SCHEMBL15416572 | 0.86 | IRAK1 (0.53) | IRAK1GPR119USP30IRAK4HPGDS | |
| SCHEMBL17781950 | 0.84 | IRAK1 (0.49) | IRAK1IRAK4 | |
| SCHEMBL16713457 | 0.83 | IRAK1 (0.53) | IRAK1GPR119USP30IRAK4WNT1 | |
| SCHEMBL15416639 | 0.83 | IRAK1 (0.53) | IRAK1GPR119USP30IRAK4WNT1 | |
| SCHEMBL15416415 | 0.83 | IRAK1 (0.53) | IRAK1GPR119USP30IRAK4WNT1 | |
| SCHEMBL15431560 | 0.82 | GPR119 (0.55) | IRAK1GPR119USP30IRAK4HPGDS | |
| SCHEMBL15431358 | 0.81 | IRAK1 (0.54) | IRAK1GPR119USP30IRAK4HPGDS | |
| SCHEMBL15416148 | 0.81 | IRAK1 (0.54) | IRAK1GPR119USP30IRAK4HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872501-B1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING SA (CH) | 2016-06-01 | — | — | EP | disclosed |
| EP-2872501-B1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING SA (CH) | 2016-06-01 | — | — | EP | disclosed |
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | disclosed |
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | disclosed |
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | disclosed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2872501-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | Ares Trading S.A. (CH) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014008992-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014008992-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | DPYD, TYMS, DHFR | IRAK1 117/4885GPR119 2437/4885USP30 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.